Oncos Therapeutics is a Helsinki, Finland–based biotech focused on developing oncolytic viruses, with a lead clinical candidate CGTG-102. The company's work is grounded in extensive scientific research at the University of Helsinki. Through its Advanced Therapy Access Program the company has treated over 200 late-stage cancer patients since 2007 with reportedly strong efficacy results. Oncos completed a €4m (approximately $5.5m) investment from HealthCap and will use the funds to advance CGTG-102 into cancer treatments. HealthCap highlighted that oncolytic viruses are maturing as a new treatment modality and noted Oncos's promising human results and strong science.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2010